Effects of the addition of mosapride to gastroesophageal reflux disease patients on proton pump inhibitor: A prospective randomized, double-blind study

Hyun Chul Lim, Jie Hyun Kim, Young Hoon Youn, Eun Hee Lee, Byung Keon Lee, Hyojin Park

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background/Aims: Proton pump inhibitors (PPIs) which are the most effective agents for the treatment of gastroesophageal reflux disease (GERD), have been known to delay gastric emptying. Mosapride has been used as prokinetics by accelerating gastric emptying. We evaluated the efficacy of mosapride to prevent PPI-induced delayed gastric emptying in a prospective randomized, double-blind and placebo-controlled trial. Methods: Thirty patients who were diagnosed as GERD and had normal gastric emptying were included in this study. PPI monotherapy group was treated with placebo drug in addition to pantoprazole and PPI plus mosapride group was treated with mosapride in addition to pantoprazole for 8 weeks. Gastric emptying scan and questionnaires about GERD and dyspeptic symptoms were assessed by scoring before and after treatment. To evaluate the changes of gastrointestinal endocrine hormones by PPI which are associated gastric acid secretion and gastric motility, fasting plasma gastrin and cholecystokinin were taken at weeks 0 and 8. Results: Half gastric emptying time was increased (P = 0.023) in PPI monotherapy group, and there were no significant changes in PPI plus mosapride group. Plasma gastrin level increased in PPI monotherpay group (P = 0.028) and there were no significant changes in PPI plus mosapride group. Plasma cholecystokinin level was not changed after treatment in both groups. GERD symptoms were improved after treatment in both groups, and postprandial bloating and nausea were improved in PPI plus mosapride group. Conclusions: Mosapride showed to be effective in preventing delayed gastric emptying and the increase in plasma gastrin level induced by PPI treatment, but did not show prominent clinical symptom improvements.

Original languageEnglish
Pages (from-to)495-502
Number of pages8
JournalJournal of Neurogastroenterology and Motility
Volume19
Issue number4
DOIs
Publication statusPublished - 2013 Oct 24

Fingerprint

Proton Pump Inhibitors
Gastroesophageal Reflux
Double-Blind Method
Gastric Emptying
Gastrins
Cholecystokinin
mosapride
Placebos
Gastrointestinal Hormones
Therapeutics
Gastric Acid
Nausea
Fasting
Stomach

All Science Journal Classification (ASJC) codes

  • Clinical Neurology
  • Gastroenterology

Cite this

@article{54fa27b96c984fcd9798c70623d22ca9,
title = "Effects of the addition of mosapride to gastroesophageal reflux disease patients on proton pump inhibitor: A prospective randomized, double-blind study",
abstract = "Background/Aims: Proton pump inhibitors (PPIs) which are the most effective agents for the treatment of gastroesophageal reflux disease (GERD), have been known to delay gastric emptying. Mosapride has been used as prokinetics by accelerating gastric emptying. We evaluated the efficacy of mosapride to prevent PPI-induced delayed gastric emptying in a prospective randomized, double-blind and placebo-controlled trial. Methods: Thirty patients who were diagnosed as GERD and had normal gastric emptying were included in this study. PPI monotherapy group was treated with placebo drug in addition to pantoprazole and PPI plus mosapride group was treated with mosapride in addition to pantoprazole for 8 weeks. Gastric emptying scan and questionnaires about GERD and dyspeptic symptoms were assessed by scoring before and after treatment. To evaluate the changes of gastrointestinal endocrine hormones by PPI which are associated gastric acid secretion and gastric motility, fasting plasma gastrin and cholecystokinin were taken at weeks 0 and 8. Results: Half gastric emptying time was increased (P = 0.023) in PPI monotherapy group, and there were no significant changes in PPI plus mosapride group. Plasma gastrin level increased in PPI monotherpay group (P = 0.028) and there were no significant changes in PPI plus mosapride group. Plasma cholecystokinin level was not changed after treatment in both groups. GERD symptoms were improved after treatment in both groups, and postprandial bloating and nausea were improved in PPI plus mosapride group. Conclusions: Mosapride showed to be effective in preventing delayed gastric emptying and the increase in plasma gastrin level induced by PPI treatment, but did not show prominent clinical symptom improvements.",
author = "Lim, {Hyun Chul} and Kim, {Jie Hyun} and Youn, {Young Hoon} and Lee, {Eun Hee} and Lee, {Byung Keon} and Hyojin Park",
year = "2013",
month = "10",
day = "24",
doi = "10.5056/jnm.2013.19.4.495",
language = "English",
volume = "19",
pages = "495--502",
journal = "Journal of Neurogastroenterology and Motility",
issn = "2093-0879",
publisher = "Korean Society of Neurogastroenterology and Motility",
number = "4",

}

Effects of the addition of mosapride to gastroesophageal reflux disease patients on proton pump inhibitor : A prospective randomized, double-blind study. / Lim, Hyun Chul; Kim, Jie Hyun; Youn, Young Hoon; Lee, Eun Hee; Lee, Byung Keon; Park, Hyojin.

In: Journal of Neurogastroenterology and Motility, Vol. 19, No. 4, 24.10.2013, p. 495-502.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of the addition of mosapride to gastroesophageal reflux disease patients on proton pump inhibitor

T2 - A prospective randomized, double-blind study

AU - Lim, Hyun Chul

AU - Kim, Jie Hyun

AU - Youn, Young Hoon

AU - Lee, Eun Hee

AU - Lee, Byung Keon

AU - Park, Hyojin

PY - 2013/10/24

Y1 - 2013/10/24

N2 - Background/Aims: Proton pump inhibitors (PPIs) which are the most effective agents for the treatment of gastroesophageal reflux disease (GERD), have been known to delay gastric emptying. Mosapride has been used as prokinetics by accelerating gastric emptying. We evaluated the efficacy of mosapride to prevent PPI-induced delayed gastric emptying in a prospective randomized, double-blind and placebo-controlled trial. Methods: Thirty patients who were diagnosed as GERD and had normal gastric emptying were included in this study. PPI monotherapy group was treated with placebo drug in addition to pantoprazole and PPI plus mosapride group was treated with mosapride in addition to pantoprazole for 8 weeks. Gastric emptying scan and questionnaires about GERD and dyspeptic symptoms were assessed by scoring before and after treatment. To evaluate the changes of gastrointestinal endocrine hormones by PPI which are associated gastric acid secretion and gastric motility, fasting plasma gastrin and cholecystokinin were taken at weeks 0 and 8. Results: Half gastric emptying time was increased (P = 0.023) in PPI monotherapy group, and there were no significant changes in PPI plus mosapride group. Plasma gastrin level increased in PPI monotherpay group (P = 0.028) and there were no significant changes in PPI plus mosapride group. Plasma cholecystokinin level was not changed after treatment in both groups. GERD symptoms were improved after treatment in both groups, and postprandial bloating and nausea were improved in PPI plus mosapride group. Conclusions: Mosapride showed to be effective in preventing delayed gastric emptying and the increase in plasma gastrin level induced by PPI treatment, but did not show prominent clinical symptom improvements.

AB - Background/Aims: Proton pump inhibitors (PPIs) which are the most effective agents for the treatment of gastroesophageal reflux disease (GERD), have been known to delay gastric emptying. Mosapride has been used as prokinetics by accelerating gastric emptying. We evaluated the efficacy of mosapride to prevent PPI-induced delayed gastric emptying in a prospective randomized, double-blind and placebo-controlled trial. Methods: Thirty patients who were diagnosed as GERD and had normal gastric emptying were included in this study. PPI monotherapy group was treated with placebo drug in addition to pantoprazole and PPI plus mosapride group was treated with mosapride in addition to pantoprazole for 8 weeks. Gastric emptying scan and questionnaires about GERD and dyspeptic symptoms were assessed by scoring before and after treatment. To evaluate the changes of gastrointestinal endocrine hormones by PPI which are associated gastric acid secretion and gastric motility, fasting plasma gastrin and cholecystokinin were taken at weeks 0 and 8. Results: Half gastric emptying time was increased (P = 0.023) in PPI monotherapy group, and there were no significant changes in PPI plus mosapride group. Plasma gastrin level increased in PPI monotherpay group (P = 0.028) and there were no significant changes in PPI plus mosapride group. Plasma cholecystokinin level was not changed after treatment in both groups. GERD symptoms were improved after treatment in both groups, and postprandial bloating and nausea were improved in PPI plus mosapride group. Conclusions: Mosapride showed to be effective in preventing delayed gastric emptying and the increase in plasma gastrin level induced by PPI treatment, but did not show prominent clinical symptom improvements.

UR - http://www.scopus.com/inward/record.url?scp=84885912304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885912304&partnerID=8YFLogxK

U2 - 10.5056/jnm.2013.19.4.495

DO - 10.5056/jnm.2013.19.4.495

M3 - Article

C2 - 24199010

AN - SCOPUS:84885912304

VL - 19

SP - 495

EP - 502

JO - Journal of Neurogastroenterology and Motility

JF - Journal of Neurogastroenterology and Motility

SN - 2093-0879

IS - 4

ER -